When sourcing plastic components for healthcare equipment or food processing machinery, understanding the distinction between medical grade and food grade materials is fundamental. These terms are not interchangeable, and each carries specific regulatory requirements, testing protocols, and market expectations. For Southeast Asian manufacturers looking to sell on Alibaba.com to global buyers, proper certification is not optional—it's the entry ticket to premium markets.
FDA (U.S. Food and Drug Administration) regulations govern food contact substances under 21 CFR Parts 174-179. The FDA defines a food contact substance as any substance intended for use as a component of materials used in manufacturing, packing, packaging, transporting, or holding food, provided such use is not intended to have any technical effect in the food [1]. This includes packaging materials, processing equipment surfaces, and storage containers. Compliance requires demonstrating that substances do not migrate into food at levels that would pose health risks.
LFGB (German Food and Feed Code) represents the European standard and is notably stricter than FDA in several dimensions. While FDA focuses primarily on total migration limits, LFGB requires testing of both total migration and specific migrated monomers. Additionally, LFGB mandates sensory evaluation—testing for odor and taste transfer—which FDA does not require [3]. For exporters targeting EU markets, LFGB certification is non-negotiable.
FDA vs LFGB: Key Testing Differences
| Testing Dimension | FDA (USA) | LFGB (Germany/EU) | Business Impact |
|---|---|---|---|
| Total Migration | Required | Required | Both standards require baseline testing |
| Specific Monomer Migration | Not required | Required | LFGB adds cost and time but provides stronger safety assurance |
| Sensory Evaluation (Odor/Taste) | Not required | Mandatory | Critical for food/beverage applications where taste contamination is unacceptable |
| Test Conditions | Standardized per 21 CFR | More stringent conditions | LFGB may reveal issues FDA testing would miss |
| Market Access | USA, North America, some Asia-Pacific | EU, Germany, countries adopting EU standards | Dual certification maximizes market reach |
ISO 10993 Biological Evaluation applies specifically to medical devices and represents the global standard for biocompatibility testing. However, a significant regulatory development emerged in early 2026: the FDA and U.S. manufacturers have formally opposed the new ISO 10993-1:2026 standard scheduled for January 2026 publication [4]. The controversy centers on three required elements: risk estimation for all materials, testing for foreseeable misuse, and end-of-life degradation testing. U.S. committee members voted against the standard, citing lack of implementation guidance and concerns about regulatory divergence.
The new ISO 10993-1:2026 standard requires risk estimation, foreseeable misuse testing, and end-of-life testing, but no implementation guidance has been provided. US manufacturers are concerned about regulatory divergence and increased testing burden without clear benefit [4].

